KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Asset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesChange in TaxesDeferred TaxesDepreciation & Amortization (CF)Dividends Paid - CommonFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Amgen (AMGN) Capital Expenditures (2016 - 2025)

Historic Capital Expenditures for Amgen (AMGN) over the last 17 years, with Q3 2025 value amounting to $436.0 million.

  • Amgen's Capital Expenditures rose 6964.98% to $436.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was $1.6 billion, marking a year-over-year increase of 6293.63%. This contributed to the annual value of $1.1 billion for FY2024, which is 143.88% down from last year.
  • According to the latest figures from Q3 2025, Amgen's Capital Expenditures is $436.0 million, which was up 6964.98% from $369.0 million recorded in Q2 2025.
  • In the past 5 years, Amgen's Capital Expenditures registered a high of $436.0 million during Q3 2025, and its lowest value of $160.0 million during Q3 2022.
  • Moreover, its 5-year median value for Capital Expenditures was $249.0 million (2023), whereas its average is $275.8 million.
  • In the last 5 years, Amgen's Capital Expenditures crashed by 3388.43% in 2022 and then soared by 8105.26% in 2023.
  • Quarter analysis of 5 years shows Amgen's Capital Expenditures stood at $287.0 million in 2021, then increased by 18.47% to $340.0 million in 2022, then dropped by 26.76% to $249.0 million in 2023, then soared by 49.0% to $371.0 million in 2024, then increased by 17.52% to $436.0 million in 2025.
  • Its Capital Expenditures was $436.0 million in Q3 2025, compared to $369.0 million in Q2 2025 and $411.0 million in Q1 2025.